UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-10, Vol.24 (10), p.2601-2606

2013

Volltextzugriff (PDF)

Serial plasma genotyping of patients with EGFR-mutant lung cancer treated with ASP8273 demonstrates acquired resistance mediated by EGFR C797S

European journal of cancer (1990), 2016-12, Vol.69, p.S27-S27

2016

Volltextzugriff (PDF)

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours

European journal of cancer (1990), 2013-03, Vol.49 (4), p.782-789

2013

Volltextzugriff (PDF)

60 - Serial plasma genotyping of patients with EGFR-mutant lung cancer treated with ASP8273 demonstrates acquired resistance mediated by EGFR C797S

European journal of cancer (1990), 2016-12, Vol.69, p.S27-S27

2016

Volltextzugriff (PDF)

Chronopharmacokinetics of Sumatriptan in Healthy Human Subjects

Journal of pharmacy and pharmacology, 2000-09, Vol.52 (9), p.1085-1090

2000

Volltextzugriff (PDF)

Lecithin vesicles for topical delivery of diclofenac

European journal of pharmaceutics and biopharmaceutics, 2003-11, Vol.56 (3), p.389-392

2003

Volltextzugriff (PDF)

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3098-3098

2011

Volltextzugriff (PDF)

A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3099-3099

2011

Volltextzugriff (PDF)

Iontophoresis of lecithin vesicles of cyclosporin A

International journal of pharmaceutics, 2004-04, Vol.274 (1), p.185-190

2004

Volltextzugriff (PDF)

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2530-2530

2010

Volltextzugriff (PDF)

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3016-3016

2010

Volltextzugriff (PDF)

Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2531-2531

2010

Volltextzugriff (PDF)

First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3006-3006

2010

Volltextzugriff (PDF)

A dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of OSI-930 and erlotinib (E) in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3550-3550

2009

Volltextzugriff (PDF)

Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3564-3564

2009

Volltextzugriff (PDF)

Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.2559-2559

2009

Volltextzugriff (PDF)

Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3544-3544

2009

Volltextzugriff (PDF)

Pharmacokinetics of Diethylcarbamazine after Single Oral Dose at Two Different Times of Day in Human Subjects

Journal of clinical pharmacology, 2002-03, Vol.42 (3), p.327-331

2002

Volltextzugriff (PDF)

Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects

Pharmacological research, 2001-03, Vol.43 (3), p.301-305

2001

Volltextzugriff (PDF)

Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30

Investigational new drugs, 2002-02, Vol.20 (1), p.23-33

2002

Volltextzugriff (PDF)

Correlation of serum and salivary levels of pentoxifylline

Therapeutic drug monitoring, 2000-08, Vol.22 (4), p.432-436

2000

Volltextzugriff (PDF)

High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasma

Journal of chromatography. B, Biomedical sciences and applications, 2001-08, Vol.759 (1), p.175-178

2001

Volltextzugriff (PDF)

Leonine Facies of Lepromatous Leprosy

JAMA dermatology (Chicago, Ill.), 2023-12, Vol.159 (12), p.1385

2023

Volltextzugriff (PDF)

Patient perspectives of wound care management in hidradenitis suppurativa

Archives of dermatological research, 2023-08, Vol.315 (6), p.1847-1850

2023

Volltextzugriff (PDF)

Leprosy-Insufficient Evidence for Monthly Multidrug Therapy-Reply

JAMA dermatology (Chicago, Ill.), 2024-07, Vol.160 (7), p.786

2024

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Englisch
(98)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Serial plasma genotyping of patients with EGFR-mutant lung cancer treated with ASP8273 demonstrates acquired resistance mediated by EGFR C797S

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours

60 - Serial plasma genotyping of patients with EGFR-mutant lung cancer treated with ASP8273 demonstrates acquired resistance mediated by EGFR C797S

Chronopharmacokinetics of Sumatriptan in Healthy Human Subjects

Lecithin vesicles for topical delivery of diclofenac

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors

A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors

Iontophoresis of lecithin vesicles of cyclosporin A

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors

Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors

First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma

A dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of OSI-930 and erlotinib (E) in patients (pts) with advanced solid tumors

Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors

Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors

Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors

Pharmacokinetics of Diethylcarbamazine after Single Oral Dose at Two Different Times of Day in Human Subjects

Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects

Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30

Correlation of serum and salivary levels of pentoxifylline

High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasma

Leonine Facies of Lepromatous Leprosy

Patient perspectives of wound care management in hidradenitis suppurativa

Leprosy-Insufficient Evidence for Monthly Multidrug Therapy-Reply

Suchergebnisse filtern